Published in Scand Cardiovasc J on June 01, 2008
How common is asymptomatic paroxysmal atrial fibrillation in chronic heart failure? Scand Cardiovasc J (2008) 0.75
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet (2008) 3.71
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 3.40
N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med (2005) 3.35
Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation (2005) 2.81
Prevalence of diastolic dysfunction as a possible cause of dyspnea in the elderly. Am J Med (2005) 2.67
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J (2008) 2.65
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care (2005) 2.59
Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol (2011) 2.29
Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar). Eur Heart J (2012) 2.21
[Cost effectiveness in the Danish health care of ezetemibe co-administration compared to simvastatin]. Ugeskr Laeger (2008) 2.03
High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors. J Hypertens (2006) 2.03
Effect of increasing pump speed during exercise on peak oxygen uptake in heart failure patients supported with a continuous-flow left ventricular assist device. A double-blind randomized study. Eur J Heart Fail (2014) 1.99
The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther (2004) 1.70
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens (2008) 1.61
Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail (2014) 1.60
Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J (2006) 1.58
Impact of fixed pulmonary hypertension on post-heart transplant outcomes in bridge-to-transplant patients. J Heart Lung Transplant (2010) 1.53
Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol (2009) 1.51
Impact of obesity on long-term prognosis following acute myocardial infarction. Int J Cardiol (2005) 1.47
Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology (2008) 1.47
Is N-terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease? Am Heart J (2006) 1.45
Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. J Hypertens (2008) 1.45
High mortality among heart failure patients treated with antidepressants. Int J Cardiol (2010) 1.42
[The Mechanical Heart--HeartMate 1--Danish results]. Ugeskr Laeger (2007) 1.40
Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol (2004) 1.38
[Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure. A retrospective analysis of 125 consecutive cases]. Ugeskr Laeger (2004) 1.38
N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension (2005) 1.31
N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J (2007) 1.30
Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J (2009) 1.26
Hemodynamic and neuroendocrine responses to changes in sodium intake in compensated heart failure. Am J Physiol Regul Integr Comp Physiol (2005) 1.12
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J (2009) 1.12
Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population. Int J Cardiol (2009) 1.11
How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail (2004) 1.05
Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol (2010) 1.04
Suspected side effects to the quadrivalent human papilloma vaccine. Dan Med J (2015) 1.04
Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups. Eur J Heart Fail (2011) 1.02
Incidence of ventricular arrhythmias in patients on long-term support with a continuous-flow assist device (HeartMate II). J Heart Lung Transplant (2009) 1.01
Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. J Card Fail (2005) 1.01
Autonomic dysfunction in HIV patients on antiretroviral therapy: studies of heart rate variability. Clin Physiol Funct Imaging (2007) 1.01
Prevalence and prognostic significance of hyponatraemia in outpatients with chronic heart failure. Eur J Heart Fail (2011) 1.00
Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J (2007) 0.99
Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. Eur Heart J (2010) 0.98
N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol (Oxf) (2004) 0.98
IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol (2008) 0.98
Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J (2005) 0.96
Increased intracranial volume in Parkinson's disease. J Neurol Sci (2005) 0.95
N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens (2004) 0.95
Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail (2006) 0.94
Decreased heart rate variability in HIV positive patients receiving antiretroviral therapy: importance of blood glucose and cholesterol. PLoS One (2011) 0.93
An integrated approach to diagnosis and therapeutic management of patients with systolic heart failure in the Copenhagen metropolitan area. Am Heart J (2002) 0.93
Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Eur J Heart Fail (2004) 0.92
Prevalence and prognostic significance of atrial fibrillation in outpatients with heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail (2006) 0.91
Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther (2005) 0.90
Kidneys extract BNP and NT-proBNP in healthy young men. J Appl Physiol (1985) (2005) 0.90
Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure. Cardiovasc Drugs Ther (2008) 0.90
Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ (2003) 0.90
Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial. Circulation (2013) 0.89
Effects of body mass index and age on N-terminal pro brain natriuretic peptide are associated with glomerular filtration rate in chronic heart failure patients. Clin Chem (2007) 0.88
Prognostic threshold levels of NT-proBNP testing in primary care. Eur Heart J (2008) 0.87
Three decades of heart transplantation in Scandinavia: long-term follow-up. Eur J Heart Fail (2012) 0.87
Patient adherence to evidence-based pharmacotherapy in systolic heart failure and the transition of follow-up from specialized heart failure outpatient clinics to primary care. Eur J Heart Fail (2013) 0.86
Adding serial N-terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study). Eur J Heart Fail (2013) 0.85
Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison. Cardiology (2004) 0.85
The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure. Am Heart J (2007) 0.84
Decreased mitochondrial oxidative phosphorylation capacity in the human heart with left ventricular systolic dysfunction. Eur J Heart Fail (2012) 0.84
Effects of a nurse-based heart failure clinic on drug utilization and admissions in a community hospital setting. Scand Cardiovasc J (2005) 0.84
A model of physical factors in the structural adaptation of microvascular networks in normotension and hypertension. Physiol Meas (2003) 0.84
Prediction of outcome by highly sensitive troponin T in outpatients with chronic systolic left ventricular heart failure. Am J Cardiol (2012) 0.84
Amino-terminal pro-B-type natriuretic peptides: testing in general populations. Am J Cardiol (2008) 0.83
Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. J Card Fail (2012) 0.83
Patients with severe acquired brain injury show increased arousal in tilt-table training. Dan Med J (2013) 0.83
The role of Lamin A/C mutations in Danish patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail (2009) 0.83
Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagn Microbiol Infect Dis (2010) 0.83
Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure. Growth Horm IGF Res (2009) 0.81
Interleukin-2 receptor antagonists as induction therapy after heart transplantation: systematic review with meta-analysis of randomized trials. J Heart Lung Transplant (2008) 0.81
Hemodynamic stress echocardiography in patients supported with a continuous-flow left ventricular assist device. JACC Cardiovasc Imaging (2010) 0.81
Constrictive pericarditis in a contemporary Danish cohort: aetiology and outcome. Scand Cardiovasc J (2015) 0.81
Neurohormones as markers of right- and left-sided cardiac dimensions and function in patients with untreated chronic heart failure. Int J Cardiol (2005) 0.81
Insulin resistance and maximal oxygen uptake. Clin Cardiol (2003) 0.81